### Schriftenverzeichnis

**Originalarbeiten**

1. Vij R, Nath R, Afar D, Mateos MV, Berdeja J, Raab M, Guenther A, Martinez-Lopez J, Jakubowiak A, Leleu X, Weisel K, Wong S, Gulbranson S, Sheridan J, Reddy A, Paiva B, Singhal A, San Miguel J, Moreau P (2020): First-in-Human Phase 1 Study of ABBV-838, an Antibody Drug Conjugate Targeting CS1 in Patients with Relapsed and Refractory Multiple Myeloma. Clinical Cancer Research April 2020; DOI: 10.1158/1078-0432.CCR-19-1431.
 IF: 8.911
2. Raab M,1 Thomas SK, Ocio EM, Guenther A, Goh YT, Talpaz M, Hohmann N, Zhao S, Xiang F, Simon C, Vanasse KG, Kumar SK (2019): The First in Human Study of the pan-PIM Kinase Inhibitor PIM447 in Patients with Relapsed and/or Refractory Multiple Myeloma.
Akzeptiert zur Publikation bei Leukemia
 IF: 12.104
3. Richardson P, Roy A, Acharyya S, Panneerselvam A, Mendelson E, Günther A, Lonial S, Einsele H (2017): Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent. Expert Rev Hematol. ***10***: 933-939.
 IF: 2.070
4. San-Miguel JF, Hungria VTM, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Guenther A, Na Nakorn T, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Salwender H, Sopala M, Redhu S, Paul S, Corrado C, Richardson PG (2017): Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial. Br J Haematol. ***179***: 66-74.
 IF: 5.812
5. Kröger N, Iacobelli S, Niederwieser D, Platzbecker U, Uddin R, Hübel K, Scheid C, Weber T, Robin M, Stelljes M, Afanasiev B, Heim D, Lambertenghi Deliliers G, Onida F, Dreger P, Pini M, Guidi S, Volin L, Günther A, Bethge W, Poiré X, Kobbe G, van Os M, Brand R, de Witte T (2017): Dose-reduced vs. standard conditioning followed by allogeneic stem cell transplantation for patients with myelodysplastic syndrome: A prospective randomized phase III study of the EBMT (RICMAC-Trial). J Clin Oncol ***35***:2157-2164.
 IF: 20.982
6. Knop S, Langer C, Engelhardt M, Mügge LO, Reichle A, Rösler W, Bassermann F, Hertenstein B, Kunitz A, Röllig C, Ostermann H, Schäfer-Eckart K, Ringhoffer M, Günther A, Junghanss C, Biersack H, Schreder M, Liebert A, Held S, Einsele H, Bargou RC (2017): Lenalidomide, adriamycin, dexamethasone for induction followed by stem-cell transplant in newly diagnosed myeloma. Leukemia ***31***:1816-1819.
 IF: 12.104
7. Guenther A, Losch E Schiessl M, Schrauder A, Humpe A, Repp R, Nitsche T, Wiltfang J, Gramatzki M (2017): Dental status does not predict infection during stem cell transplantation - a single-center survey. Bone Marrow Transplant ***52***:1041-1043.
 IF: 3.636
8. Burger R, Günther A, Klausz K, Staudinger M, Peipp M, Rose-John S, Wijdenes J, Gramatzki M (2017): Due to interleukin-6 type cytokine redundancy, only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth. Haematologica ***102***:381-390.
 IF: 6.671
9. San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Na Nakorn T, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Binlich F, Richardson PG (2016): Panobinostat plus bortezomib and dexamethasone: final analysis of overall survival from the randomized, placebo-controlled, phase 3 PANORAMA 1 trial. Lancet Haematol ***3***: e506-e515.
 IF: 4.889
10. Kellner C, Günther A, Humpe A, Repp R, Klausz K, Derer S, Valerius T, Ritgen M, Brüggemann M, van de Winkel J.G. Parren P, Kneba M, Gramatzki M, Peipp M (2016): Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30: Oncoimmunology ***5***: e1058459.
 IF: 7.644
11. Richardson PG, Vânia TMH., Soo Yoon SS, Beksac M, Dimopoulos MA,5 Elghandour A,6 Jedrzejczak WW, Guenther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Corrado C, San-Miguel JF (2016): Panobinostat plus bortezomib and dexamethasone in relapsed/relapsed and refractory myeloma: Outcomes by priortreatment . Blood ***127***:713-21.
 IF: 11.847
12. Delforge M, Devos T, Rowe J, Espanol I, Durrant ST, Raddoux J, Boogaerts M, Gramatzki M, Guenther A (2016): Lack of clinical benefit of zoledronic acid in myelofibrosis: results of a prospective multicenter phase II trial. Leukemia and Lymphoma ***57***, 470-473.
 IF: 3.093
13. Borggrefe J, Giravent S, Thomsen F, Peña J, Campbell G, Wulff A, Günther A, Heller M, Glüer CC (2015): [Association of QCT bone mineral density and bone structure with vertebral fractures in patients with multiple myeloma.](http://www.ncbi.nlm.nih.gov/pubmed/25545497) J Bone Miner Res ***30***:1329-37.
 IF: 5.622
14. [Wehkamp U](http://www.ncbi.nlm.nih.gov/pubmed/?term=Wehkamp%20U%5BAuthor%5D&cauthor=true&cauthor_uid=26053561), [Oschlies I](http://www.ncbi.nlm.nih.gov/pubmed/?term=Oschlies%20I%5BAuthor%5D&cauthor=true&cauthor_uid=26053561), [Nagel I](http://www.ncbi.nlm.nih.gov/pubmed/?term=Nagel%20I%5BAuthor%5D&cauthor=true&cauthor_uid=26053561), [Brasch J](http://www.ncbi.nlm.nih.gov/pubmed/?term=Brasch%20J%5BAuthor%5D&cauthor=true&cauthor_uid=26053561), [Kneba M](http://www.ncbi.nlm.nih.gov/pubmed/?term=Kneba%20M%5BAuthor%5D&cauthor=true&cauthor_uid=26053561), [Günther A](http://www.ncbi.nlm.nih.gov/pubmed/?term=G%C3%BCnther%20A%5BAuthor%5D&cauthor=true&cauthor_uid=26053561), [Klapper W](http://www.ncbi.nlm.nih.gov/pubmed/?term=Klapper%20W%5BAuthor%5D&cauthor=true&cauthor_uid=26053561), [Weichenthal M](http://www.ncbi.nlm.nih.gov/pubmed/?term=Weichenthal%20M%5BAuthor%5D&cauthor=true&cauthor_uid=26053561) (2015): ALK-positive primary cutaneous T-cell-lymphoma (CTCL) with unusual clinical presentation and aggressive course. [J Cutan Pathol](http://www.ncbi.nlm.nih.gov/pubmed/?term=gunther+weichenthal) ***42***:870-7.
 IF: 1.409
15. [Guenther A](http://www.ncbi.nlm.nih.gov/pubmed/?term=Guenther%20A%5BAuthor%5D&cauthor=true&cauthor_uid=25682600), [Baumann P](http://www.ncbi.nlm.nih.gov/pubmed/?term=Baumann%20P%5BAuthor%5D&cauthor=true&cauthor_uid=25682600), [Burger R](http://www.ncbi.nlm.nih.gov/pubmed/?term=Burger%20R%5BAuthor%5D&cauthor=true&cauthor_uid=25682600), [Kellner C](http://www.ncbi.nlm.nih.gov/pubmed/?term=Kellner%20C%5BAuthor%5D&cauthor=true&cauthor_uid=25682600), [Klapper W](http://www.ncbi.nlm.nih.gov/pubmed/?term=Klapper%20W%5BAuthor%5D&cauthor=true&cauthor_uid=25682600), [Schmidmaier R](http://www.ncbi.nlm.nih.gov/pubmed/?term=Schmidmaier%20R%5BAuthor%5D&cauthor=true&cauthor_uid=25682600), [Gramatzki M](http://www.ncbi.nlm.nih.gov/pubmed/?term=Gramatzki%20M%5BAuthor%5D&cauthor=true&cauthor_uid=25682600) (2015): Everolimus (RAD001) Activity in relapsed and/or refractory multiple myeloma: A phase I study. Haematologica ***100***:541-7.
 IF: 6.671
16. Borggrefe J, Giravent S, Thomsen F, Peña J, Campbell G, Wulff A, Günther A, Heller M, Glüer CC (2015): [Association of QCT bone mineral density and bone structure with vertebral fractures in patients with multiple myeloma.](http://www.ncbi.nlm.nih.gov/pubmed/25545497) J Bone Miner Res ***30***:1329-37.
 IF: 5.622
17. San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Na Nakorn T, Siritanaratkul N, Corradini P, Chuncharunee S, Lee JJ, Schlossman RL, Shelekhova T, Yong K, Tan D, Numbenjapon T, Cavenagh JD, Hou J, LeBlanc R, Nahi H, Qiu L, Salwender H, Pulini S, Moreau P, Warzocha K, White D, Bladé J, Chen W, de la Rubia J, Gimsing P, Lonial S, Kaufman JL, Ocio EM, Veskovski L, Sohn SK, Wang MC, Lee JH, Einsele H, Sopala M, Corrado C, Bengoudifa BR, Binlich F, Richardson PG (2014): [Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.](http://www.ncbi.nlm.nih.gov/pubmed/25242045) Lancet Oncol ***15***:1195-206.
 IF: 26.509
18. Staudinger M, Glorius P, Burger R, Kellner C, Klausz K, Günther A, Repp R, Klapper W, Gramatzki M, Peipp M (2014): [The novel immunotoxin HM1.24-ETA' induces apoptosis in multiple myeloma cells.](http://www.ncbi.nlm.nih.gov/pubmed/24927408) Blood Cancer J ***4***: e219.
 IF: 4.411
19. San-Miguel JF, Richardson PG, Günther A, Sezer O, Siegel D, Bladé J, LeBlanc R, Sutherland H, Sopala M, Mishra KK, Bourquelot PM, Mateos MV, Anderson KC (2013): A Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma. J Clin Oncol ***31***:3696-703.
 IF: 20.982
20. Czayszynska A\*, Günther A\*, Humpe A, Schub N, Raff T, Schrauder A, Nickelsen M, Repp R, Schrappe M, Kneba M, Gramatzki M (2013): Allogeneic Stem Cell Transplantation with BEAM and Alemtuzumab Conditioning Immediately after Remission Induction has Curative Potential in Advanced T-cell NHL. Biol Blood Marrow Transplant ***19***:1632-7. \*gemeinsame Erstautorenschaft
 IF: 3.980
21. Humpe A, Buwitt-Beckmann U, Schub N, Gramatzki M, Günther A (2013):Successful mobilization, intra-apheresis recruitment, and harvest of hematopoietic progenitor cells by addition of plerixafor and subsequent large volume apheresis. Transfus Med Hemother ***40***:2 51-7.
 IF: 2.160
22. [Beck-Broichsitter BE](http://www.ncbi.nlm.nih.gov/pubmed/?term=Beck-Broichsitter%20BE%5BAuthor%5D&cauthor=true&cauthor_uid=23453026), [Klapper W](http://www.ncbi.nlm.nih.gov/pubmed/?term=Klapper%20W%5BAuthor%5D&cauthor=true&cauthor_uid=23453026), [Günther A](http://www.ncbi.nlm.nih.gov/pubmed/?term=G%C3%BCnther%20A%5BAuthor%5D&cauthor=true&cauthor_uid=23453026), [Wiltfang J](http://www.ncbi.nlm.nih.gov/pubmed/?term=Wiltfang%20J%5BAuthor%5D&cauthor=true&cauthor_uid=23453026), [Becker ST](http://www.ncbi.nlm.nih.gov/pubmed/?term=Becker%20ST%5BAuthor%5D&cauthor=true&cauthor_uid=23453026) (2013): Gingival ulceration and exposed bone. [Oral Surg Oral Med Oral Pathol Oral Radiol.](http://www.ncbi.nlm.nih.gov/pubmed/23453026) ***115***:288-92.
 IF: 1.262
23. Schub N, Günther A, Schrauder A, Claviez A, Ehlert C, Repp R, Gramatzki M (2011): Therapy of steroid-refractory acute graft-versus-host disease with CD52 Antibody Alemtuzumab is effective. Bone Marrow Transplant ***46***:143-7.
 IF: 3.636
24. Guenther A, Gordon S, Tiemann M, Burger R, Bakker F, Green JR, Baum W, Roelofs AJ, Rogers MJ, Gramatzki M (2010): The bisphosphonate zoledronic acid has anti-myeloma activity *in vivo* by inhibition of protein prenylation, Int J Cancer ***126***:239-46.
 IF: 5.531
25. Metzner A, Precht C, Fehse B, Fiedler W, Stocking C , Günther A, Mayr GW, Jücker M (2009): Reduced proliferation of CD34+ cells from patients with acute myeloid leukemia after gene transfer of *INPP5D* encoding the inositol 5-phosphatase SHIP1. Gene Ther ***16***:570-3.
 IF: 3.242
26. Burger R, Bakker F, Guenther A, Baum W, Schmidt-Arras D, Hideshima T, Tai Y-T, Shringarpure R, Catley L, Senaldi G, Gramatzki M, Anderson K (2003): Functional significance of novel neurotropin-1/B cell stimulating factor-3 (cardiotropin-like cytokine) for human myeloma cell growth and survival. British Journal of Haematology ***123***:869-878.
 IF: 5.812
27. Burger R, Guenther A, Bakker F, Schmalzing M, Bernand S, Baum W, Duerr B, Hocke GM, Steininger H, Gebhart E, Gramatzki M (2001): Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma. Hematology J ***2***:42-53.
 IF: 6.671
28. Jücker M, Günther A, Faletto DL, Gradl G, Fonatsch C, Krueger GRF, Diehl V, Van de Woude GF, Tesch H (1994): The Met/Hepatocyte growth factor receptor (HGFR) gene is overexpressed in some cases of human leukemia and lymphoma. Leuk Res ***18***: 7-16.
 IF: 2.606
29. Krueger GRF, Guenther A, Knuefermann A, Klueppelberg U, Luka J, Pearson GR, Ablashi DV, Juecker M, Tesch H: Human herpesvirus-6 (HHV-6) in Hodgkin's disease (1994): Cellular expression of viral antigens as compared to the oncogenes met and fes, the tumor suppressor gene product p53 and the interleukin 2 and 6. in vivo ***8***: 501-516.
 IF: 0.200
30. Tesch H, Günther A, Abts H, Jücker M, Klein S, Krueger GRF, Diehl V (1993): Expression of IL-2Rα and IL-2Rß in Hodgkin's disease. Am J Pathol ***142***: 1714-1720.
 IF: 4.206
31. Tesch H, Jücker M, Klein S, Abts H, Günther A, Krüger GRF., Diehl V (1992): Hodgkin and Reed-Sternberg cells express interleukin 6 Receptors. Leuk Lymphoma ***7***: 297-303.
 IF: 3.093
32. Jücker M, Merz H, Günther A, von Kalle C, Schaadt M, Diamantstein T, Feller AC, Krueger GRF, Diehl V, Blankenstein T, Tesch H (1990): Expression of Interleukin 6 and Interleukin 6 receptor in Hodgkin's disease. Blood ***77***: 2413-2418.
 IF: 11.847

IF=Impact Factor

**Übersichtsarbeiten/Reviews:**

1. Engelhardt M, Ihorst G, Caers J, Günther A, Wäsch R (2016): Autotransplants in older multiple myeloma patients: hype or hope in the era of novel agents? Haematologica. ***101***:1276-1278.
2. [Balke L](http://www.ncbi.nlm.nih.gov/pubmed?term=Balke%20L%5BAuthor%5D&cauthor=true&cauthor_uid=24845526), [Günther A](http://www.ncbi.nlm.nih.gov/pubmed?term=G%C3%BCnther%20A%5BAuthor%5D&cauthor=true&cauthor_uid=24845526), [Zeuner R](http://www.ncbi.nlm.nih.gov/pubmed?term=Zeuner%20R%5BAuthor%5D&cauthor=true&cauthor_uid=24845526), [Bewig B](http://www.ncbi.nlm.nih.gov/pubmed?term=Bewig%20B%5BAuthor%5D&cauthor=true&cauthor_uid=24845526) (2014): Eosinophilia - inflammation, proliferation, reaction. Part 2: Specific diseases. [Dtsch Med Wochenschr](http://www.ncbi.nlm.nih.gov/pubmed/24845526) ***139***:1175-80.
3. [Balke L](http://www.ncbi.nlm.nih.gov/pubmed?term=Balke%20L%5BAuthor%5D&cauthor=true&cauthor_uid=24845526), [Günther A](http://www.ncbi.nlm.nih.gov/pubmed?term=G%C3%BCnther%20A%5BAuthor%5D&cauthor=true&cauthor_uid=24845526), [Zeuner R](http://www.ncbi.nlm.nih.gov/pubmed?term=Zeuner%20R%5BAuthor%5D&cauthor=true&cauthor_uid=24845526), [Bewig B](http://www.ncbi.nlm.nih.gov/pubmed?term=Bewig%20B%5BAuthor%5D&cauthor=true&cauthor_uid=24845526) (2014): Eosinophilia - inflammation, proliferation, reaction. Part 1: Diagnostics. [Dtsch Med Wochenschr](http://www.ncbi.nlm.nih.gov/pubmed/24801301) ***139***:1053-8.
4. Green JR, Guenther A (2011): The backbone of progress — preclinical studies and innovations with zoledronic acid. Crit Rev Oncol Hematol ***77*** Suppl 1: S3-S12.